Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Φάρμακα Α - Ζ  Συγχορήγηση  Μητρότητα

Nimbex Injection 2mg/ml (2012)

Αναφορές

Βιβλιογραφική αναφορά

Στοιχεία εκδότη

Εκδότης :
GlaxoSmithKline UK
Διεύθυνση :
Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Name of the medicinal product

Nimbex 2mg/ml solution for injection/infusion.

Qualitative and quantitative composition

Cisatracurium 2mg as cisatracurium besilate 2.68mg per 1ml. One ampoule of 2.5ml contains 5mg of cisatracurium. One ampoule of 5ml contains 10mg of cisatracurium. One ampoule of 10ml contains 20mg of cisatracurium. ...

Pharmaceutical form

Solution for injection/infusion. Colourless to pale yellow or greenish yellow solution. Practically free from visible particulate matter.

Therapeutic indications

Nimbex is an intermediate-duration, non-depolarising neuromuscular blocking agent for intravenous administration. Nimbex is indicated for use during surgical and other procedures and in intensive care ...

Posology and method of administration

Nimbex should only be administered by or under the supervision of anaesthetists or other clinicians who are familiar with the use and action of neuromuscular blocking agents. Facilities for tracheal intubation, ...

Contraindications

Nimbex is contra-indicated in patients known to be hypersensitive to cisatracurium, atracurium, or benzenesulfonic acid.

Special warnings and precautions for use

Product specific topics Cisatracurium paralyses the respiratory muscles as well as other skeletal muscles but has no known effect on consciousness or pain threshold. Nimbex should be only administered ...

Interaction with other medicinal products and other forms of interaction

Many drugs have been shown to influence the magnitude and/or duration of action of non-depolarising neuromuscular blocking agents, including the following: Increased Effect: By anaesthetic agents such ...

Pregnancy and lactation

There are no adequate data from the use of Nimbex in pregnant women. Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal development, parturition and postnatal development ...

Effects on ability to drive and use machines

This precaution is not relevant to the use of Nimbex. Nimbex will always be used in combination with a general anaesthetic and therefore the usual precautions relating to performance of tasks following ...

Undesirable effects

Data from pooled internal clinical trials were used to determine the frequency of very common to uncommon adverse reactions. The following convention has been used for the classification of frequency:- ...

Overdose

Symptoms and signs Prolonged muscle paralysis and its consequences are expected to be the main signs of overdosage with Nimbex. Management It is essential to maintain pulmonary ventilation and arterial ...

Pharmacodynamic properties

Cisatracurium is a neuromuscular blocking agent. ATC code: M03AC11 Cisatracurium is an intermediate-duration, non-depolarising benzylisoquinolinium skeletal muscle relaxant. Clinical studies in man indicated ...

Pharmacokinetic properties

Cisatracurium undergoes degradation in the body at physiological pH and temperature by Hofmann elimination (a chemical process) to form laudanosine and the monoquaternary acrylate metabolite. The monoquaternary ...

Preclinical safety data

Acute toxicity Meaningful acute studies with cisatracurium could not be performed. For symptoms of toxicity see "Overdosage" Subacute Toxicity: Studies with repeated administration for three weeks in dogs ...

List of excipients

Benzene sulfonic acid solution 32% w/v Water for injections

Incompatibilities

Degradation of cisatracurium besilate has been demonstrated to occur more rapidly in lactated Ringers Injection and 5% Dextrose and lactated Ringers Injection than in the infusion fluids listed under Section ...

Shelf life

Shelf life before dilution: 2 years. Chemical and physical in-use stability has been demonstrated for at least 24 hours at 5°C and 25°C (see section 6.6). From a microbiological point of view, the product ...

Special precautions for storage

Store in a refrigerator (2°C to 8°C). Do not freeze. Store in the original package in order to protect from light For storage conditions of the diluted medicinal product see section 6.3.

Nature and contents of container

Nimbex 2mg/ml solution for injection/infusion. 2.5ml in ampoule (glass): box of 5 5ml in ampoule (glass): box of 5 10ml in ampoule (glass): box of 5 25ml in ampoule (glass: box of 2 Type I, clear, neutral ...

Special precautions for disposal and other handling

This product is for single use only. Use only clear and almost colourless up to slightly yellow/greenish yellow coloured solutions. The product should be visually inspected before use, and if the visual ...

Marketing authorization holder

The Wellcome Foundation Limited 980 Great West Road Brentford Middlesex TW8 9GS United Kingdom Trading as: GlaxoSmithKline UK Stockley Park West Uxbridge Middlesex UB11 1BT

Marketing authorization number(s)

PL 00003/0364

Date of first authorization / renewal of the authorization

Date of first authorisation: 07 August 1995 Date of last renewal: 09 August 2010

Date of revision of the text

6 November 2012